Transcripta Bio, Mayo Clinic join force on ALS therapies

Transcripta Bio has entered into a research collaboration and licensing agreement with Mayo Clinic to identify potential treatments and therapeutic targets for ALS. Mayo Clinic is prospectively recruiting living ALS patients through an Institutional Review Board-approved protocol. The work aims to elucidate how ALS biology varies across patients and accelerate the development of targeted therapies. Credit: Faizal Ramli/Shutterstock.com. Transcripta Bio has entered into a research collaboration and licensing agreement with Mayo Clinic to identify potential treatments and therapeutic targets for amyotrophic lateral sclerosis (ALS). The initiative centres on creating a high-resolution, patient-derived molecular map of the fatal neurodegenerative disorder, which…

Salong Debbarma · 2026-10-16

Transcripta Bio has entered into a research collaboration and licensing agreement with Mayo Clinic to identify potential treatments and therapeutic targets for ALS.

Source: Pharmaceutical Technology